GlassScriptPhysician profile
Danielle Bianca Vance
NPI 1912777566
$2,215.93
in general payments reported to CMS, 2019-2025
16 companies · $921 in 2025
The $921 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,295 · 2025: $921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,909 · Education: $307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,908.73 |
| Education | $307.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $368.07 | 2024-2025 | |
| Astellas Pharma US INC | $350.26 | 2024 | Cresemba |
| Janssen Biotech, INC. | $252.51 | 2024 | Talvey, Tecvayli, Darzalex |
| Regeneron Healthcare Solutions, INC. | $128.27 | 2025 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $123.76 | 2025 | Iclusig |
| Genmab U.S., INC. | $122.51 | 2025 | Epkinly |
| Servier Pharmaceuticals LLC | $122.30 | 2025 | |
| Amgen INC. | $118.42 | 2024 | Blincyto |
| Pfizer INC. | $116.57 | 2025 | |
| Beigene USA, INC. | $116.18 | 2024 | Brukinsa |
| Lilly USA, LLC | $112.21 | 2024 | |
| Pharmaessentia USA Corporation | $102.36 | 2025 | Besremi |
| Genzyme Corporation | $102.00 | 2024 | |
| Azurity Pharmaceuticals, INC. | $28.97 | 2025 | Danziten |
| Incyte Corporation | $26.71 | 2025 | Monjuvi, Zynyz |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $24.83 | 2025 | Xt Cdx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Vance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.